US2881113A - Therapeutically active compositions containing amphetamines - Google Patents

Therapeutically active compositions containing amphetamines Download PDF

Info

Publication number
US2881113A
US2881113A US636866A US63686657A US2881113A US 2881113 A US2881113 A US 2881113A US 636866 A US636866 A US 636866A US 63686657 A US63686657 A US 63686657A US 2881113 A US2881113 A US 2881113A
Authority
US
United States
Prior art keywords
mgm
amphetamines
amphetamine
magnesium trisilicate
aluminum hydroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US636866A
Inventor
Millman Max
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to US636866A priority Critical patent/US2881113A/en
Application granted granted Critical
Publication of US2881113A publication Critical patent/US2881113A/en
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Description

United States Patent THERAPEUTICALLY ACTIVE COMPOSITIONS CONTAINING AMPHETAMINES Max Millman, Springfield, Mass, assignor 'to' Ortho lyharmaceutical Corporation, a corporation of New ersey N0 Drawing. Application January 29, 1957 Serial No. 636,866

3 Claims. (Cl. 167-55) This invention relates to new and improved compositions consisting of amphetamine compounds and has particular relation to a new and useful therapeutic agent containing the aforementioned compounds. More specifically, the present invention relates to amphetamine compounds such as dl-amphetamine sulfate, dl-amphetamine hydrochloride, dextroamphetamine sulfate, and methamphetamine hydrochloride, combined with critical amounts of an amphoteric antacid such as aluminum hydroxide, magnesium trisilicate, or dihydroxy aluminum aminoacetate. The compositions of my invention are appetite satients effective for the treatment of obesity.

The amphetamines are used not infrequently in the treatment of mental depression, narcolepsy, lethargy and several other conditions. Their most common use, however, is as appetite depressants in the treatment of overweight and obesity.

It is well known that amphetamine compounds such as amphetamine sulfate and hydrochloride, dextroamphetamine sulfate, methamphetamine hydrochloride, etc., act as stimulants for the central nervous system and are capable of exerting valuable effects in the treatment of obesity. However, said compounds have also certain undesirable gastrointestinal effects, such as heartburn, nausea, vomiting, and diarrhea. These symptoms are not infrequently observed in patients receiving amphetamine compounds.

It is the main object of the present invention to provide an amphetamine composition, the beneficial eifects of which are greater and the undesirable side eflfects of which are less than known amphetamine compositions.

It is another object of the present invention to improve the action of amphetamine compounds by buffering or combining them with critical amounts of amphoteric antacids such as aluminum hydroxide, magnesium trisilicate, and dihydroxy aluminum aminoacetate.

Another object of the present invention is to provide a therapeutic agent, the anorexigenic or appetite-depressant effects of which are higher than those of the amphetamines alone.

Still another object of this invention is to reduce the undesirable side effects such as epigastric distress and heartburn which are occasionally encountered with the amphetamines alone.

Other objects and advantages of the invention will be apparent from the appended claims and the following specification which describes by way of example some embodiments of the invention.

I have now discovered that the appetite depressing action of amphetamines may be synergized and the undesirable side efiects of amphetamine compounds reduced by combining or buffering them with critical amounts of certain amphoteric antacids. More specifically, the novel appetite satient composition of the present invention includes, in addition to the amphetamine compound or mixture of amphetamine compounds, at least 8 milli-equivalents of a mixture of aluminum hy- 2 dioxide, magnesium trisilicate, and dihydroxyaluminum aminoacetate.

The amphetamine compound which I have found effective in my compositions is dextroamphetamine (dextro-l-phenyl-2-aminopropane). It is known that this compound is more effective when mixed with the dlamphetamine. I prefer to use in a single dosage unit approximately 3 mgm. of an amphetamine compound such as dextroamphetamine sulfate together with 3 mgm. of dl-amphetamine sulfate. To this I add at least .8- milliequivalents of a mixture of aluminum hydroxide and magnesium trisilicate. To minimize the occasional undesirable stimulation of the nervous system caused by administering amphetamine compounds, I may. add to my composition a sedative such as amytal (5-ethy1-5- isoamyl barbituric acid), barbital. (5,5'-diethyl barbituric acid), or phenobarbital 5-ethyl-5'-phenyl barbituric acid) in variable doses.

Because of their amphoteric character, there is no critical limitation on the maximum amount of antacid that is present in my compositions. As magnesium trisilicate is a laxative and large amounts of aluminum hydroxide would cause constipation, it is desirable 'to combine these two antacids. Satisfactory compositions prepared according to this invention contain about two or three parts by weight of magnesium trisilicate to one part by weight of aluminum hydroxide. Dihydroxy= aluminum amino'acetate may be substituted in whole or in part for the aluminum hydroxide.

My compositions may more conveniently be used i171 the form of tablets of lozenges (pleasant tasting). The

tablets may be prepared by mixing the active'ingredients (amphetamine compounds, barbiturates, magnesium trisilicate, and aluminum hydroxide) with excipients (sugar, talc, corn starch and binders) and flavoring oils (oil of peppermint, oil of fennel and methyl salicylate). The tablet may be prepared by processes well known in the pharmaceutical line, such as by slugging or by a wet granulation process. Lozenges containing similar dosage of active ingredients may also be prepared by known methods. It is an advantage of the lozenges that they' may be chewed and swallowed without the aid of water.

As the amphetamines are most effective when taken about one-half to one hour before meals when water is not always readily available for administration, the lozenges are a most convenient dosage form.

Granulate part A with 10% gelatin solution and dry at 50 C. Regranulate and mix with B. Compress into tablets weighing 1183.5 mgm.

EXAMPLE II Ingredient: Per tablet, mgm. A. Dextroamphetamine sulfate 3.5 Methamphetamine hydrochloride 1.5 Amytal 20.0 Aluminum hydroxide 110.0 Magnesium trisilicate 350.0

B. Starch 4.25 Magnesium stearate 4.25

Granulate part A with 10% gelatin solution. Dry at Compress .into

with the exception that the aluminum hydroxide and magnesium trisilicate were omitted. The amphetamines were in the same dosage as noted for group I.

The 10 patients in group III were a control group. These patients received antacids (aluminum hydroxide and magnesium trisilicate) alone.

The clinical results are tabulated in Table I.

Table 1 Average Number Total lbs. lost Group of Treatment lbs. lost, per

patients 8 wks. patlent per week I 26 Amphetamines and antacids... 479 2. 30 II 26 Amphetamines alone 261 1. III..... 10 Antacids alone 0 It is apparent that there is a significant difference in the degree of weight loss induced by the three treatments. It may be noted that the antacids have no appetite-depressing action. Since, however, upon combination with amphetamines the anorexigenic effect of the latter was enhanced, it may be concluded that the antacids pro- EXAMPLE .111 Ingredient: Per tablet, mgm. A. Dextroamphetamine sulfate up 5.0 Amytal 15.0 Aluminum hydroxide 250.0 Magnesium trisilicate 500.0 B. Starch 4.25 Magnesium stearate 4.25 -Granulate part A with 10% gelatin solution and dry at 50 C. Regranulate and mix with B. Compress into tablets weighing 778.5 mgm.

EXAMPLE IV Ingredient: Per tablet, mgm. AJBextroamphetamine sulfate 3.0 dl-Amphetamine sulfate 3.0 Amytal 30.0 Aluminum hydroxide 110.0 Magnesium trisilicate 600.0 Dixhydroxy aluminum aminoacetate 300.0 E. Sucrose 1000.0

I Granulate part A with 10% gelatin solution and dry at ,50' C. Regranulate and mix with B. Compress into lozenges weighing 2,046 mgm.

"The proportions of the various ingredients of my composition may be varied widely. The amphetamine comperiod may vary from about 3 to about 6 mgm. per dosage unit. The barbiturate may be eliminated entirely or may be present in an amount up to approximately mgm. The lower limit of the amphoteric antacid is critical as too small an amount is not effective. I have found that at least 4 milli-equivalents of aluminum hydroxide (104 mgm.) in combination with at least 4 mini-equivalents of magnesium trisilicate (350 mgm.) is required to synergize the appetite depressing action of amphetamines. An equivalent amount of dihydroxy aluminum aminoacetate may be substituted for the aluminum hydroxide. Since the amphoteric antacids employed are non-toxic, the upper limit of the amount of antacid present is not critical.

"The practical effect of my amphetamine compositions may be appreciated from clinical results on 62 unselected overweight patients ranging in age from 17 to 72 years and in weight from 132 to 291 pounds. These patients were divided into three groups and treated for a period of eight weeks. The 26 patients in group I were treated with tablets prepared according to Example I. Dosage wasthre'e tablets daily about one-half to one hour before meals, yielding a total of 15 mgm. of amphetamines perday.

Group II also consisted of 26 patients similarly treated What is claimed is:

duced a synergistic effect with the amphetamines. Experimental findings in laboratory animals corroborate this observation.

In addition to the better results observed with the use of aluminum hydroxide and magnesium trisilicate, the patients in group I reported less hunger and fewer gastrointestinal side effects such as heartburn, nausea, vomiting and diarrhea.

1. An obesity control composition suitable for oral administration comprising in the following relative proportions, 3-4 mgm. of a dextroamphetamine compound, 1-2 mgm. of d-methamphetamine hydrochloride, 0-20 mgm. of S-ethyl-S-isoamyl barbituric acid, 4 milli-equivalents of aluminum hydroxide, and 4 milli-equivalents of magnesium trisilicate.

2. An obesity control composition suitable for oral administration comprising in the following relative pro-. portions, 3 mgm. of dextroamphctamine sulfate, 3 mgm. of dl-amphetamine hydrochloride, 20 mgm. of S-ethyl-S- isoamyl barbituric acid, 350 mgm. of aluminum hydroxide, and 800 mgm. of magnesium trisilicate.

3. An obesity control composition suitable for oral of a mixture of amphetamine compounds and at least 8 milli-equivalents of a mixture of aluminum hydroxide and magnesium trisilicate.

References Cited in the file of this patent Wilson: The American Drug Index, 1956, Lippincott Co., Philadelphia, Pa., PP. 292 and 337.

Claims (1)

1. AN OBESITY CONTROL COMPOSITION SUITABLE FOR ORAL ADMINISTRATION COMPRISING IN THE FOLLOWING RELATIVE PROPORTIONS, 3-4 MGM. OF A DEXTROAMPHETAMINE COMPOUND, 1-2 MGM. OF D-METHAMPHETAMINE HYDROCHLORIDE, O-20 MGM. OF 5-ETHYL-5-ISOAMYL BARBITURIC ACID, 4 MILLI-EQUIVALENTS OF ALUMIUNM HYDROXIDE, AND 4 MILLI-EQUIVALENTS OF MAGNESIUM TRISILICATE.
US636866A 1957-01-29 1957-01-29 Therapeutically active compositions containing amphetamines Expired - Lifetime US2881113A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US636866A US2881113A (en) 1957-01-29 1957-01-29 Therapeutically active compositions containing amphetamines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US636866A US2881113A (en) 1957-01-29 1957-01-29 Therapeutically active compositions containing amphetamines

Publications (1)

Publication Number Publication Date
US2881113A true US2881113A (en) 1959-04-07

Family

ID=24553665

Family Applications (1)

Application Number Title Priority Date Filing Date
US636866A Expired - Lifetime US2881113A (en) 1957-01-29 1957-01-29 Therapeutically active compositions containing amphetamines

Country Status (1)

Country Link
US (1) US2881113A (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369967A (en) * 1962-11-21 1968-02-20 Lab D Analyses Et De Rech S Bi Compositions for treating obesity and methods of use
US4581232A (en) * 1983-07-20 1986-04-08 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates
US4632823A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of appetite suppressants
US4632822A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antiasmatics
US4632821A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of decongestants
US4642231A (en) * 1983-07-20 1987-02-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
US4643892A (en) * 1983-07-20 1987-02-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of analgesics
US4643898A (en) * 1983-07-20 1987-02-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of nutritional supplements and laxatives
US4647459A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Confectionery compositions containing magnesium trisilicate adsorbates
US4647449A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of alkaloids
US4647450A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Chewing gum compositions containing magnesium trisilicate absorbates
US4649041A (en) * 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
US4650663A (en) * 1983-07-20 1987-03-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
US20040219213A1 (en) * 1998-10-21 2004-11-04 Burnside Beth A. Oral pulsed dose drug delivery system
US20060127473A1 (en) * 2004-12-13 2006-06-15 Nichols William M Compositions and methods for stabilizing active pharmaceutical ingredients
US20070264323A1 (en) * 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
US20080139653A1 (en) * 2006-12-11 2008-06-12 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
US20080207757A1 (en) * 2007-02-08 2008-08-28 Mickle Travis C Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369967A (en) * 1962-11-21 1968-02-20 Lab D Analyses Et De Rech S Bi Compositions for treating obesity and methods of use
US4643898A (en) * 1983-07-20 1987-02-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of nutritional supplements and laxatives
US4632823A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of appetite suppressants
US4632822A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antiasmatics
US4632821A (en) * 1983-07-20 1986-12-30 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of decongestants
US4642231A (en) * 1983-07-20 1987-02-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
US4643892A (en) * 1983-07-20 1987-02-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of analgesics
US4581232A (en) * 1983-07-20 1986-04-08 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates
US4647459A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Confectionery compositions containing magnesium trisilicate adsorbates
US4647449A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of alkaloids
US4647450A (en) * 1983-07-20 1987-03-03 Warner-Lambert Company Chewing gum compositions containing magnesium trisilicate absorbates
US4649041A (en) * 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
US4650663A (en) * 1983-07-20 1987-03-17 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
USRE42096E1 (en) * 1998-10-21 2011-02-01 Shire LLC, USA Oral pulsed dose drug delivery system
US20040219213A1 (en) * 1998-10-21 2004-11-04 Burnside Beth A. Oral pulsed dose drug delivery system
US20060127473A1 (en) * 2004-12-13 2006-06-15 Nichols William M Compositions and methods for stabilizing active pharmaceutical ingredients
US20070264323A1 (en) * 2006-05-12 2007-11-15 Shire Llc Controlled dose drug delivery system
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US9173857B2 (en) 2006-05-12 2015-11-03 Shire Llc Controlled dose drug delivery system
US20080139653A1 (en) * 2006-12-11 2008-06-12 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
US8101661B2 (en) 2006-12-11 2012-01-24 Kempharm, Inc. Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same
US20100292336A1 (en) * 2006-12-11 2010-11-18 Mickle Travis C Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same
WO2008073918A1 (en) * 2006-12-11 2008-06-19 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
US7776917B2 (en) 2006-12-11 2010-08-17 Mickle Travis C Non-standard amino acid conjugates of amphetamine and processes for making and using the same
US20100292337A1 (en) * 2007-02-08 2010-11-18 Mickle Travis C Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same
US20080207757A1 (en) * 2007-02-08 2008-08-28 Mickle Travis C Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same
US7772222B2 (en) 2007-02-08 2010-08-10 Mickle Travis C Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same

Similar Documents

Publication Publication Date Title
US3488418A (en) Sustained relief analgesic composition
Sands et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
CA1198057A (en) Method of contraception using peak progestogen dosage
Yongchaiyudha et al. Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus
CA1319887C (en) Non-steroidal anti-inflammatory compositions protected against gastro-intestinal injury with a combination of certain h _and h _receptor blockers
SU1443788A3 (en) Method of producing solid medicine
US5273754A (en) Appetite suppressant composition and method relating thereto
Ehrensing et al. Melanocyte-stimulating hormone-release inhibiting hormone as an antidepressant: a pilot study
US4866046A (en) Low-dosage sublingual aspirin
US5273759A (en) Method and composition for treating the migraine complex
CA1176981A (en) Method for preventing body fat deposition in mammals
Curtis et al. Efficacy of ipecac and activated charcoal/cathartic: Prevention of salicylate absorption in a simulated overdose
US3253988A (en) Antacid composition and method of using same
US2887438A (en) Prolonged action tablets
US4393071A (en) Method of treating gastric, mammary, lung and uterus tumors
DE19541128C2 (en) Stabilized thyroid hormone-containing medicines
US3898328A (en) Dry stable composition for the treatment of scours and dehydration
KR970007188B1 (en) Composition for treating gastrointestinal disorders
FR2488508A1 (en) Alkaline analgesic capsule
GB1576376A (en) Multiple-unit drug dose
FR2559061A1 (en) Analgesic and anti-inflammatory compositions containing diphenhydramine
CZ290691B6 (en) Pharmaceutical preparation
Davidow et al. Tissue distribution, accumulation and elimination of the isomers of benzene hexachloride
FUJII et al. Teratogenicity of caffeine in mice related to its mode of administration
EP0428296B1 (en) Pharmaceutical compositions for treating gastrointestinal distress